Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

[Factors predicting the failure of interruption of highly active antiretroviral treatment (HAART) in HIV-infected patients].

Cervero-Jiménez M, Torres-Perea R, Ruiz-Capillas JJ, del Alamo M, Agud JL, Solís J, Bouzas E.

Enferm Infecc Microbiol Clin. 2005 Apr;23(4):202-7. Spanish.

PMID:
15826544
2.

[Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].

Pavie J, Porcher R, Fournier S, André F, Tournoux C, Palmer P, Rabian C, Jean-Michel M.

Presse Med. 2005 Jun 4;34(10 Suppl):1S8-13. French.

PMID:
16025661
3.

Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.

Porter BO, Anthony KB, Shen J, Hahn B, Keh CE, Maldarelli F, Blackwelder WC, Lane HC, Kovacs JA, Davey RT, Sereti I.

AIDS. 2009 Jan 14;23(2):203-12. doi: 10.1097/QAD.0b013e32831cc114.

4.

Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.

Nemes E, Lugli E, Nasi M, Ferraresi R, Pinti M, Bugarini R, Borghi V, Prati F, Esposito R, Cossarizza A, Mussini C.

AIDS. 2006 Oct 24;20(16):2021-32.

PMID:
17053348
5.

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.

PMID:
24852077
6.

CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.

Boschi A, Tinelli C, Ortolani P, Moscatelli G, Morigi G, Arlotti M.

AIDS. 2004 Dec 3;18(18):2381-9.

PMID:
15622314
7.

Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.

Ruiz L, Paredes R, Gómez G, Romeu J, Domingo P, Pérez-Alvarez N, Tambussi G, Llibre JM, Martínez-Picado J, Vidal F, Fumaz CR, Clotet B; TIBET Study Group..

AIDS. 2007 Jan 11;21(2):169-78.

PMID:
17197807
8.

Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study.

Mussini C, Pinti M, Bugarini R, Borghi V, Nasi M, Nemes E, Troiano L, Guaraldi G, Bedini A, Sabin C, Esposito R, Cossarizza A.

AIDS. 2005 Oct 14;19(15):1627-33.

PMID:
16184032
9.

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.

Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K.

Clin Infect Dis. 2005 Mar 1;40(5):728-34.

10.

A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.

Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, Ruxrungtham K, Hirschel B, Lange J, Phanuphak P, Cooper DA.

Clin Infect Dis. 2005 Feb 15;40(4):594-600.

11.

CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.

Mussini C, Bedini A, Borghi V, Guaraldi G, Esposito R, Barchi E, Enilia R, Cozzi-Lepri A, Philips AN, Ortolani P, Bratt G, Eriksson LE, Sighinolfi L, Cossarizza A, d'Arminio Monforte A, De Luca A, Di Giambenedetto S, Antinori A; International Study Group on CD4-monitored Treatment Interruptions..

AIDS. 2005 Feb 18;19(3):287-94.

PMID:
15718839
12.

Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.

Moltó J, Ruiz L, Romeu J, Martínez-Picado J, Negredo E, Tural C, Sirera G, Clotet B.

AIDS Res Hum Retroviruses. 2004 Dec;20(12):1283-8.

PMID:
15650419
13.

Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.

Sanchez R, Portilla J, Gimeno A, Boix V, Llopis C, Sanchez-Paya J, Merino E, de la Sen ML, Muñoz C, Reus S, Plazas J.

J Infect. 2007 Feb;54(2):159-66.

PMID:
16690132
14.

Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.

Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.

HIV Med. 2007 Jan;8(1):46-54.

15.

Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/microL: a randomized trial.

Krolewiecki AJ, Zala C, Vanzulli C, Pérez H, Iannella Mdel C, Bouzas MB, Gun A, Valiente J, Cassetti I, Cahn P.

J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):425-9.

PMID:
16652049
16.

Thymic volume predicts CD4 T-cell decline in HIV-infected adults under prolonged treatment interruption.

Molina-Pinelo S, Vivancos J, De Felipe B, Soriano-Sarabia N, Valladares A, De la Rosa R, Vallejo A, Leal M.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):203-6.

PMID:
16760798
17.

Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.

Achenbach CJ, Till M, Palella FJ, Knoll MD, Terp SM, Kalnins AU, Murphy RL.

HIV Med. 2005 Jan;6(1):7-12.

18.

Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).

Pogány K, van Valkengoed IG, Prins JM, Nieuwkerk PT, van der Ende I, Kauffmann RH, Kroon FP, Verbon A, Nievaard MF, Lange JM, Brinkman K.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):395-400. Erratum in: J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):607. Vanvalkengoed, Irene G [corrected to van Valkengoed, Irene G M].

PMID:
17195761
19.

A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.

Piketty C, Weiss L, Assoumou L, Burgard M, Mélard A, Ragnaud JM, Bentata M, Girard PM, Rouzioux C, Costagliola D; ANRS 116 SALTO Study Group..

J Med Virol. 2010 Nov;82(11):1819-28. doi: 10.1002/jmv.21907.

PMID:
20872707
20.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
Items per page

Supplemental Content

Support Center